CLINICAL SIGNIFICANCE OF HFE C282Y AND H63D HETEROZYGOSITY: A REVIEW OF CURRENT GUIDELINES AND EVIDENCE
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6734Keywords:
HFE, Haemochromatosis, C282Y, H63D, Heterozygosity, Iron OverloadAbstract
With the increasing availability of genetic testing, individuals heterozygous for the C282Y or H63D variant of the HFE gene are being identified more frequently. Although clinical management is better established for patients homozygous for C282Y, recommendations for those with heterozygous HFE genotypes remain less clearly defined. This narrative review included 29 sources identified through searches of PubMed and Google Scholar, and screening of the reference lists of relevant publications. It aimed to synthesise the available evidence on the clinical risk associated with HFE heterozygosity and to assess the appropriateness of diagnostic and therapeutic interventions in this population. The evidence base included professional society guidelines and position statements, observational studies, case reports, and review articles addressing genotype-phenotype relationships in HFE-related haemochromatosis. The available data indicate that heterozygosity for a single C282Y or H63D variant rarely results in clinically significant iron overload and do not support routine dietary restrictions or prophylactic phlebotomy in individuals with iron indices within normal limits. Similar conclusions apply to C282Y/H63D compound heterozygosity, although this genotype is associated with a slightly higher clinical risk. The review also highlights the limited guidance on family testing when the proband is a heterozygous carrier, as well as the clinical consequences of overinterpreting H63D. Overall, these findings support a phenotype-guided approach to the diagnostic and therapeutic management of individuals heterozygous for HFE variants.
References
Abeyagunawardena, I., Mayura, S., Samarasingha, P., Nawinne, A., & Karunatilake, H. (2024). Iron overload in histidine-to-aspartic acid substitution at 63 (H63D) gene heterozygous hereditary hemochromatosis with erythrocytosis: A case report. Cureus, 16(12), e76335. https://doi.org/10.7759/cureus.76335
Aguilar-Martinez, P., Grandchamp, B., Cunat, S., Cadet, E., Blanc, F., Nourrit, M., Lassoued, K., Schved, J.-F., & Rochette, J. (2011). Iron overload in HFE C282Y heterozygotes at first genetic testing: A strategy for identifying rare HFE variants. Haematologica, 96(4), 507–514. https://doi.org/10.3324/haematol.2010.029751
Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M., Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C., Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K., Powell, L. W., & Gertig, D. M. (2008). Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine, 358(3), 221–230. https://doi.org/10.1056/NEJMoa073286
Aranda, N., Viteri, F. E., Montserrat, C., & Arija, V. (2010). Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Annals of Hematology, 89(8), 767–773. https://doi.org/10.1007/s00277-010-0901-9
Barton, J. C., & Parker, C. J. (2024). HFE-related hemochromatosis. In M. P. Adam, S. Bick, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, & A. Amemiya (Eds.), GeneReviews® [Internet]. University of Washington, Seattle. Retrieved August 2026, from https://www.ncbi.nlm.nih.gov/books/NBK1440/ (Original work published 2000)
Beaton, M. D., & Adams, P. C. (2012). Treatment of hyperferritinemia. Annals of Hepatology, 11(3), 294–300. https://doi.org/10.1016/S1665-2681(19)30923-8
Burke, W., Imperatore, G., McDonnell, S. M., Baron, R. C., & Khoury, M. J. (2000). Contribution of different HFE genotypes to iron overload disease: A pooled analysis. Genetics in Medicine, 2(5), 271–277. https://doi.org/10.1097/00125817-200009000-00001
de Wert, G., van El, C. G., Clarke, A., Cordier, C., Fellmann, F., Genuardi, M., Hentze, S., Kayserili, H., Macek, M., MacLeod, R., Melegh, B., Mendes, Á., Rial-Sebbag, E., Stefánsdóttir, V., Tranebjærg, L., Ulph, F., & Forzano, F. (2026). Cascade counselling and testing. Recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 34(2), 171–184. https://doi.org/10.1038/s41431-025-01945-3
European Association for the Study of the Liver. (2022). EASL clinical practice guidelines on haemochromatosis. Journal of Hepatology, 77(2), 479–502. https://doi.org/10.1016/j.jhep.2022.03.033
Fabri, R. F. S., Rodrigues, R. M. D. M., & Prabakar, D. (2026). Severe hepatic iron overload and cirrhosis in an HFE C282Y heterozygote with autoimmune hepatitis: A case of genotype-phenotype discordance. Cureus, 18(3), e105851. https://doi.org/10.7759/cureus.105851
Ginzburg, Y. Z. (2019). Hepcidin-ferroportin axis in health and disease. Vitamins and Hormones, 110, 17–45. https://doi.org/10.1016/bs.vh.2019.01.002
Greenwood, D. C., Cade, J. E., Moreton, J. A., O'Hara, B., Burley, V. J., Randerson-Moor, J. A., Kukalizch, K., Thompson, D., Worwood, M., & Bishop, D. T. (2005). HFE genotype modifies the influence of heme iron intake on iron status. Epidemiology, 16(6), 802–805. https://doi.org/10.1097/01.ede.0000181306.85583.ea
Grosse, S. D., Gurrin, L. C., Bertalli, N. A., & Allen, K. J. (2018). Clinical penetrance in hereditary hemochromatosis: Estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genetics in Medicine, 20(4), 383–389. https://doi.org/10.1038/gim.2017.121
Gurrin, L. C., Bertalli, N. A., Dalton, G. W., Osborne, N. J., Constantine, C. C., McLaren, C. E., English, D. R., Gertig, D. M., Delatycki, M. B., Nicoll, A. J., Southey, M. C., Hopper, J. L., Giles, G. G., Anderson, G. J., Olynyk, J. K., Powell, L. W., & Allen, K. J. (2009). HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology, 50(1), 94–101. https://doi.org/10.1002/hep.22972
Hasan, S. M. M., Farrell, J., & Borgaonkar, M. (2022). C282Y/H63D compound heterozygosity is a low penetrance genotype for iron overload-related disease. Journal of the Canadian Association of Gastroenterology, 5(5), 240–247. https://doi.org/10.1093/jcag/gwac025
Hunt, J. R., & Zeng, H. (2004). Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. American Journal of Clinical Nutrition, 80(4), 924–931. https://doi.org/10.1093/ajcn/80.4.924
Infanti, L., Leitner, G., Moe, M., Pehlic, V., Cattaneo, M., Benkert, P., Holbro, A., Passweg, J., Worel, N., & Buser, A. (2024). Blood donation for iron removal in individuals with HFE mutations: Study of efficacy and safety and short review on hemochromatosis and blood donation. Frontiers in Medicine, 11, 1362941. https://doi.org/10.3389/fmed.2024.1362941
Jackson, H. A., Carter, K., Darke, C., Guttridge, M. G., Ravine, D., Hutton, R. D., Napier, J. A., & Worwood, M. (2001). HFE mutations, iron deficiency and overload in 10,500 blood donors. British Journal of Haematology, 114(2), 474–484. https://doi.org/10.1046/j.1365-2141.2001.02949.x
Kowdley, K. V., Brown, K. E., Ahn, J., & Sundaram, V. (2019). ACG clinical guideline: Hereditary hemochromatosis. American Journal of Gastroenterology, 114(8), 1202–1218. https://doi.org/10.14309/ajg.0000000000000315
Moretti, D., van Doorn, G. M., Swinkels, D. W., & Melse-Boonstra, A. (2013). Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: A systematic review. American Journal of Clinical Nutrition, 98(2), 468–479. https://doi.org/10.3945/ajcn.112.048264
Nemeth, E., & Ganz, T. (2023). Hepcidin and iron in health and disease. Annual Review of Medicine, 74, 261–277. https://doi.org/10.1146/annurev-med-043021-032816
Porto, G., Brissot, P., Swinkels, D. W., Zoller, H., Kamarainen, O., Patton, S., Alonso, I., Morris, M., & Keeney, S. (2016). EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). European Journal of Human Genetics, 24(4), 479–495. https://doi.org/10.1038/ejhg.2015.128
Roe, M. A., Heath, A. L. M., Oyston, S. L., Macrow, C., Hoogewerff, J. A., Foxall, R., Dainty, J. R., Majsak-Newman, G., Willis, G., & Fairweather-Tait, S. J. (2005). Iron absorption in male C282Y heterozygotes. American Journal of Clinical Nutrition, 81(4), 814–821. https://doi.org/10.1093/ajcn/81.4.814
Shearman, J., Olynyk, J. K., Distante, S., Porto, G., & Sanchez, M. (2026). HFE and hemochromatosis: Time to reconsider the diagnostic role of the p.His63Asp variant. Blood Red Cells & Iron, 2(1), 100034. https://doi.org/10.1016/j.brci.2025.100034
Speechley, M., Alter, D., Guo, H., Harrison, H., & Adams, P. C. (2012). Effect of ambiguous hemochromatosis gene test results on physician utilization. Medical Care, 50(5), 394–398. https://doi.org/10.1097/MLR.0b013e318245a06e
Turbiville, D., Du, X., Yo, J., Jana, B. R., & Dong, J. (2019). Iron overload in an HFE heterozygous carrier: A case report and literature review. Laboratory Medicine, 50(2), 212–217. https://doi.org/10.1093/labmed/lmy065
Vears, D. F., Boyle, J., Jacobs, C., McInerney-Leo, A., & Newson, A. J. (2023). Human Genetics Society of Australasia position statement: Genetic carrier testing for recessive conditions. Twin Research and Human Genetics, 26(2), 188–194. https://doi.org/10.1017/thg.2023.15
Walsh, A., Dixon, J. L., Ramm, G. A., Hewett, D. G., Lincoln, D. J., Anderson, G. J., Subramaniam, V. N., Dodemaide, J., Cavanaugh, J. A., Bassett, M. L., & Powell, L. W. (2006). The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clinical Gastroenterology and Hepatology, 4(11), 1403–1410. https://doi.org/10.1016/j.cgh.2006.07.009
Zaloumis, S. G., Allen, K. J., Bertalli, N. A., Turkovic, L., Delatycki, M. B., Nicoll, A. J., McLaren, C. E., English, D. R., Hopper, J. L., Giles, G. G., Anderson, G. J., Olynyk, J. K., Powell, L. W., & Gurrin, L. C. (2015). The natural history of HFE simple heterozygosity for C282Y and H63D: A prospective twelve year study. Journal of Gastroenterology and Hepatology, 30(4), 719–725. https://doi.org/10.1111/jgh.12804
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Alicja Szemberg, Martyna Stawicka, Weronika Patrycja Polar, Ewa Weronika Pływak, Zuzanna d’Obyrn, Julia Sadowska, Karolina Strzelecka, Ewa Jagodzińska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
